# Task: AI Anticancer System Visual Assets Generation

## Overview
Create 10 high-quality images and 12 detailed tables based on the AI anticancer cocktail therapy research paper.

---

## Images (10 Total)

### System Architecture & Methodology
- [ ] **Image 1**: Complete System Architecture Diagram
  - AI-based Drug Discovery System (ADDS) framework
  - Data flow: Clinical data → Cellpose → ML models → Recommendations
  - Component integration visualization

- [ ] **Image 2**: Cellpose Cell Analysis Workflow
  - Cell segmentation process visualization
  - Vector flow prediction demo
  - Feature extraction pipeline

- [ ] **Image 3**: Multi-modal Neural Network Architecture
  - Input layers: Clinical data + Cell features
  - Hidden layers structure
  - Output: Efficacy, Synergy, Toxicity predictions

### Performance & Results
- [ ] **Image 4**: Model Performance Dashboard (Updated)
  - Ensemble model accuracy: 92.4%
  - Cellpose GPU performance: 15x faster
  - Clinical validation: 91.2%
  - Patient prognosis improvement

- [ ] **Image 5**: Drug Synergy Interaction Heatmap
  - Drug pairs matrix
  - Color-coded synergy scores
  - Pritamab combinations highlighted

- [ ] **Image 6**: Clinical Trial Results - Efficacy Comparison
  - FOLFOX vs FOLFOX+Pritamab
  - FOLFIRI vs FOLFIRI+Pritamab
  - Box plots with statistical significance

### Clinical Analysis
- [ ] **Image 7**: Toxicity Profile Radar Chart
  - Multi-dimensional toxicity comparison
  - Standard therapy vs AI-recommended therapy
  - Safety profile visualization

- [ ] **Image 8**: Patient Subgroup Forest Plot
  - Hazard ratios by subgroups
  - Age groups, KRAS status, Cancer stage, ECOG
  - Confidence intervals

- [ ] **Image 9**: ROC Curves for Prediction Models
  - Efficacy prediction (AUC)
  - Synergy prediction (AUC)
  - Toxicity prediction (AUC)

- [ ] **Image 10**: Kaplan-Meier Survival Analysis
  - Progression-free survival curves
  - Overall survival curves
  - Treatment group comparisons

---

## Tables (12 Total)

### Study Design & Setup
- [ ] **Table 1**: Patient Demographics and Baseline Characteristics
  - Total cohort: 1,000 patients (CRC 400, Lung 300, Breast 300)
  - Age distribution, Gender, Cancer type, Stage, ECOG status

- [ ] **Table 2**: Drug Database Comprehensive List
  - Drug names (including Pritamab)
  - Mechanism of action
  - FDA approval status
  - Base efficacy and toxicity scores

- [ ] **Table 3**: Cellpose Analysis Configuration
  - Parameter settings (diameter: 30, flow_threshold: 0.4, cellprob_threshold: 0.0)
  - Processing time benchmarks
  - Feature extraction specifications

### Model Specifications
- [ ] **Table 4**: Extracted Cell Morphological Features
  - Area, Circularity, N/C ratio, Atypia index
  - Calculation formulas
  - Normal vs Cancer range values

- [ ] **Table 5**: AI Model Hyperparameters
  - Random Forest: n_estimators, max_depth
  - Gradient Boosting: learning_rate, n_estimators
  - Neural Network: architecture, activation, optimizer
  - Ensemble strategy

- [ ] **Table 6**: Model Performance Metrics (All Models)
  - Accuracy, Precision, Recall, F1-score, AUC-ROC
  - Cross-validation results
  - Comparison across models

### Clinical Results
- [ ] **Table 7**: Colorectal Cancer Treatment Results - FOLFOX Group
  - FOLFOX alone: Efficacy 0.82, Synergy 1.25, Toxicity 4.2, Score 0.88
  - FOLFOX+Pritamab: Efficacy 0.95, Synergy 1.50, Toxicity 4.8, Score 1.19
  - Improvement: +35.2%

- [ ] **Table 8**: Colorectal Cancer Treatment Results - FOLFIRI Group
  - FOLFIRI alone: Efficacy 0.79, Synergy 1.22, Toxicity 4.5, Score 0.82
  - FOLFIRI+Pritamab: Efficacy 0.92, Synergy 1.45, Toxicity 5.1, Score 1.11
  - Improvement: +35.3%

- [ ] **Table 9**: Subgroup Analysis by Patient Characteristics
  - KRAS mutant vs wild-type
  - Age <70 vs ≥70
  - Stage III vs Stage IV
  - ECOG 0-1 vs 2+
  - Efficacy and interaction p-values

### Safety & Performance
- [ ] **Table 10**: Adverse Events Profile (CTCAE Grade 3/4)
  - Nausea/Vomiting, Diarrhea, Neutropenia, Neuropathy
  - Frequency comparison: Standard vs Pritamab-enhanced
  - Statistical significance

- [ ] **Table 11**: Computational Performance Benchmarks
  - Processing time per patient
  - Memory usage (CPU vs GPU)
  - Scalability metrics (100, 500, 1000 patients)
  - Hardware specifications

- [ ] **Table 12**: Comparison with Other AI Drug Discovery Systems
  - System name, Year, Accuracy, Data modalities
  - DeepSynergy, AuDNNSynergy, vs ADDS
  - Unique features of ADDS (Cellpose integration)

---

## Technical Specifications

### Image Requirements
- Resolution: 300 DPI minimum
- Size: 3000×2000 pixels (landscape) or 2000×3000 (portrait)
- Format: PNG (primary), SVG/PSD (for editing)
- Color scheme: Professional scientific journal style (Nature/Science)
- Font: Arial/Helvetica for labels, 10-14pt minimum
- All text in Korean with English subtitles where appropriate

### Table Requirements
- Format: PNG for embedding, Excel for editing, LaTeX for publishing
- Professional styling: Headers, gridlines, color-coding
- All values with appropriate precision (2-3 decimal places)
- Statistical annotations (*, **, *** for p-values)
- Clear units specified for all measurements

---

## Progress Tracking
- Total: 22 assets (10 images + 12 tables)
- Completed: 0/22
- In Progress: 0/22
- Blocked: 0/22
